Search Result "tyrosine kinase domain (TKD)"
Membrane Tyrosine Kinase Receptors are an Important Target for the Therapy of Acute Myeloid Leukemia
Journal: Current Cancer Therapy Reviews
Volume: 4 Issue: 1 Year: 2008 Page: 31-49
Author(s): Ugo Testa
Membrane Tyrosine Kinase Receptors Kit and FLT3 are an Important Targets for the Therapy of Acute Myeloid Leukemia
Journal: Current Cancer Therapy Reviews
Volume: 9 Issue: 3 Year: 2013 Page: 181-219
Author(s): Ugo Testa
Flt3 Receptor Tyrosine Kinase as a Drug Target in Leukemia
Journal: Current Pharmaceutical Design
Volume: 10 Issue: 1 Year: 2004 Page: 1867-1883
Author(s): Dirk Schmidt-Arras, Joachim Schwable, Frank- D. Bohmer, Hubert Serve
Proteomics Approaches to Elucidate Oncogenic Tyrosine Kinase Signalingin Myeloid Malignancies
Journal: Current Pharmaceutical Biotechnology
Volume: 7 Issue: 3 Year: 2006 Page: 185-198
Author(s): Eystein Oveland, Kari E. Fladmark, Line Wergeland, Bjorn Tore Gjertsen, Randi Hovland
Detection and Therapeutic Implications of c-Met Mutations in Small Cell Lung Cancer and Neuroendocrine Tumors
Journal: Current Pharmaceutical Design
Volume: 19 Issue: 5 Year: 2013 Page: 833-840
Author(s): J. Voortman,T. Harada,R.P. Chang,J.K. Killian,M. Suuriniemi,W.I. Smith,P.S. Meltzer,M. Lucchi,Y. Wang,G. Giaccone
Developments of Fms-like Tyrosine Kinase 3 Inhibitors as AnticancerAgents for AML Treatment
Journal: Current Medicinal Chemistry
Volume: 31 Issue: 29 Year: 2024 Page: 4657-4686
Author(s):
Molecular Design and Clinical Development of VEGFR Kinase Inhibitors
Journal: Current Topics in Medicinal Chemistry
Volume: 7 Issue: 1 Year: 2007 Page: 1379-1393
Author(s): Zhong Haizhen, Bowen Phillip J.
The Role of FLT3 Kinase as an AML Therapy Target
Journal: Current Pharmaceutical Design
Volume: 18 Issue: 19 Year: 2012 Page: 2758-2765
Author(s): Michal Beffinger,Anna Skwarska
The Development of PDGF Receptor Inhibitors for the Treatment of Glioma: A Review
Journal: Letters in Drug Design & Discovery
Volume: 7 Issue: 4 Year: 2010 Page: 290-299
Author(s): Michael A. Badruddoja, Emad Elquza, James Welsh, Laurence Cooke, Abhay Sanan, Baldassrre Stea, Daruka Mahadavan
Second-Generation Protein Kinase Inhibitor â A Focus on Quizartinib, A Promising Targeted Therapy for High-Risk FLT3+ Patients with Acute Myeloid Leukemia
Ebook: Frontiers in Clinical Drug Research - Anti-Cancer Agents
Volume: 5 Year: 2019
Author(s): Xavier Thomas,Etienne Paubelle
Doi: 10.2174/9789811405150119050003